6 MESSAGE OF GREETING EASD Diabetes is often underestimated and that is probably why it is is the world's most common metabolic disease. More than 415 million people suffer from diabetes - and this figure is set to increase. In Germany, too, it has long been a widespread disease. According to estimates, one in ten people here will be affected by 2030 if we do not manage to do something major to counteract it. Young people are also increasingly at risk. This is an alarming trend.
Ab durch die Hecke (Originaltitel Over the Hedge) ist ein US-amerikanischer Animationsfilm aus dem Jahre 2006. Er wurde von DreamWorks Animation produziert und in Deutschland von United International Pictures verliehen. Der Film basiert auf dem Comic Over the Hedge von Michael Fry und T.
What makes the matter particularly difficult is that diabetes is often only diagnosed Photo: Bundesregierung/Steffen Kugler when serious health problems emerge which can massively restrict quality of life and earning capacity or even reduce life expectancy. That is why prevention and early detection are so important. At the same time, we remain dependent on further advances in research so we can develop the best possible treatments. The German Government thus supports the German Center for Diabetes Research (DZD) - a cluster of excellent research institutions focusing on the challenge of diabetes in all its facets. International research cooperation is decisive in the fight against diabetes.
I am thus very grateful to the European Association for the Study of Diabetes for its wide range of work in the fields of training, research and innovation. With this the world's largest specialist congress, it is furthering scientific exchange and helping ensure that new research and development findings benefit those affected as quickly as possible.
Allow me to take this opportunity to wish all those taking part in the 52nd EASD Annual Meeting a successful and beneficial time in Munich. Angela Merkel The Federal Chancellor The Federal Republic of Germany 4. 9 LOCAL ORGANISING COMMITTEE Chairman Hans J. Hauner, Munich Members Martin Hrabe de Angelis, Munich Jochen Seissler, Munich Matthias Tschoep, Munich Anette Ziegler, Munich EASD 7 10 The mission of EASD is to promote excellence in diabetes care through research and education EASD Since its foundation in 1965, EASD has been organising an Annual Meeting, which has become the largest international annual conference on diabetes research worldwide. Although the meetings have grown so dramatically, they are still driven by the academic traditions of the founding members. The EASD Meeting is a meeting of members where guests are welcome. Chairpersons of oral presentations and poster sessions are chosen exclusively from the EASD membership.
The abstracts are evaluated on a strictly anonymous basis and the selection is based exclusively on the quality of the science, regardless of the place of work. The EASD Honorary Secretary is solely responsible for inviting speakers and chairpersons for symposia and lectures. Comments, advice and proposals from the membership and the Programme Committee are welcome. None of the speakers or chairpersons at the EASD Annual Meeting receives an honorarium; reimbursement of their travel costs is exclusively provided by the Association. EASD and its Foundation EFSD are academic charities dedicated to diabetes research. As an academic society, EASD encourages cooperation with industry and other institutions conducting and funding diabetes research.
EASD is committed to transparency. In 2005, its Annual Meeting endorsed the following policy with respect to duality of interest: prior to the Meeting speakers invited to symposia or lectures declare to EASD the existence of any relationship or arrangement that could be reasonably considered to affect the content of the presentation. Invited speakers who declare a duality of interest are asked by EASD to disclose this on a slide of their presentation. Any occasional, positive balance resulting from the Annual Meeting is used to encourage further diabetes research in Europe. Increasingly, major endpoint related trials are carried out to evaluate diabetes treatments.
EASD encourages these trials and provides an outstanding forum to announce their results to the scientific community. 11 The EASD regulations on the presentation of major clinical trials state that all data of the trial must be openly available, and clear information should be provided on the role of the funding source/sponsor on study design, data collection, analysis and interpretation of the data. Moreover, a commentator, nominated by the EASD Honorary Secretary, must have prior access to the data in order to prepare an unbiased review. EASD Meetings are organised in such a way as to ensure the academic independence of physicians and scientists as the patients' advocates. Article 1, Section 2 Statutes of the European Association for the Study of Diabetes, Diabetologia 1, (1965): EASD The aims of the Association are to encourage and support research in the field of diabetes, to rapidly spread acquired knowledge and to facilitate its application.
31 Piero Marchetti, IT David R. Matthews, UK EASD Pirjo Nuutila, FI Peter Rossing, DK Jay S. 37 AssociAtions village The Associations Village is a special exhibition area, organised by EASD in collaboration with IDF Europe, which brings together international diabetes associations, societies and study groups. Each represented association, society and study group has an exhibition stand displaying its current activities and highlighting its work and practices. The Associations Village is a multinational networking platform which aims to further increase and facilitate the exchange of knowledge and experiences among diabetes associations, and to provide information to physicians and researchers from all over the world on the existing professional and patient associations. At the Associations Village you will have the opportunity to learn about diabetes in a variety of different countries, speak with colleagues and receive the latest information on diabetes research from all over Europe, and beyond.
Representatives at each stand will be happy to answer any questions. Associations village opening Hours: Tuesday - Thursday 09:30-17:00 Friday 09:30-12:00 35. 58 tuesday, 13 september AlBeRt RenolD PRiZe The Albert Renold Prize and Lecture honours the memory of A. Renold, the distinguished diabetologist and researcher. The aim of the Lectureship is to recognise an individual's outstanding contribution to the advancement of knowledge in the field of research on the islets of Langerhans. Not only do many generations of scientists consider A.
Renold their principal mentor, but he was also one of the founding fathers of EASD, serving as Honorary Secretary ( ) and President ( ). He trained with the eminent diabetologist, Dr. Joslin, and was the first full-time director of the Joslin Research Laboratory in the mid- 1950s. In 1963, he returned to Geneva, where he founded the lnstitut de Biochimie Clinique. Under his leadership, it became an international centre of excellence in islet research until his death in P. Langerhans Jr. Was born in Berlin and entered the famous School of the Grey Monastery in the same city.
He began medical studies at the University of Jena and completed them in Berlin. The discovery of the islets of Langerhans was published in his thesis in Later he became Professor of Pathology in Freiburg. He also gained fame due to his discovery of the Langerhans cells in the skin. In 1887, while living on the island of Madeira, progressive renal failure brought his medical activities to an end and he died of uraemia in A. Renold AlBeRt RenolD lecturers 2007 Amsterdam F.
AsHcRoFt, UK 2008 Rome J.-c. HenQUin, Be 2009 vienna B. Thorens, ch 2010 stockholm s. Seino, JP 2011 lisbon M.
PRentKi, ca 2012 Berlin D.l. Eizirik, Be 2013 Barcelona P.
RoRsMAn, UK 2014 vienna s.e. KAHn, Us 2015 stockholm A. HAtteRsleY, UK 56 P. Langerhans Jr. 78 easd-novo nordisk Foundation Diabetes Prize for excellence EASD, in partnership with the Novo Nordisk Foundation, is again pleased to announce the Diabetes Prize for Excellence which was awarded for the first time in Wednesday, 14 september The EASD-Novo Nordisk Foundation Diabetes Prize for Excellence is to be awarded to an internationally recognised researcher who has contributed significantly to our understanding of diabetes and/or its treatment.
The Prize winner s research may focus on prevention, treatment and/or basic research in physiological biochemistry. The awardee will deliver a keynote lecture after the award ceremony. The history of the Novo Nordisk Foundation commences in 1922 when August Krogh, who received the Nobel Prize for Physiology/Medicine in 1920, returned from Canada and the United States holding permission to produce insulin in the Nordic countries. In 1923, the first Foundation was formed - Nordisk Insulinlaboratorium and Nordisk Insulin Foundation which should become the forerunners for the Novo Nordisk Foundation.
Today, the Novo Nordisk Foundation is an independent foundation with the vision to improve the health and welfare of people by contributing to research and development. DiABetes PRiZe FoR excellence lecturer 2015 stockholm sir s.
O Rahilly, UK 76. 123 Speaker: S. Kooijman, Netherlands Title: Time to heat up: targeting brown adipose tissue Speaker: F. D Addio, Italy Title: B lymphocytes in type 1 diabetes: destruction and regulation Friday, 16 September Speaker: N.K.A. Sandholm, Finland Title: Genetic background of diabetic nephropathy in subjects with type 1 diabetes Speaker: A.G.
Jones, UK Title: Clinical insights from C-peptide measurement 121 124 12:15 naunyn Hall easd/jdrf symposium: the intestinal microbiome in type 1 diabetes Chair: A.G. Ziegler, Germany, M. Knip, Finland Friday, 16 september M. Knip, Finland: Relationship between the maternal gut microbiome and the developing gut microbiome in the offspring R.J.
Xavier, UsA: Metagenomics to hygiene hypothesis J.F. Petrosino, UsA: Role of the intestinal microbiome in the development of beta cell autoimmunity and type 1 diabetes in young children: the teddy study Kussmaul Hall empa-reg outcome: one year later Chair: M. Walker, UK B. Zinman, canada: introduction and context D. Fitchett, canada: Macrovascular and heart failure outcomes: an update c. Wanner, germany: Microvascular and renal outcomes: an update H.c. Gerstein, canada: implications for the management of patients with type 2 diabetes and high cv risk: the diabetologist s perspective 122.